Actively Recruiting
Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)
Led by Parc Sanitari Pere Virgili · Updated on 2025-06-11
300
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether a patient-centered medication review by a multidisciplinary team can improve treatment adequacy for older adults admitted to an intermediate care hospital. This study focuses on reducing the average number of medications taken per patient by comparing this approach to the usual care, which involves a medication review by a clinical pharmacist alone. Participants will be randomly assigned to either the intervention group receiving a comprehensive medication review by a team including geriatricians, pharmacists, and nurses, or the control group receiving standard care led by a clinical pharmacist. The intervention is based on a detailed evaluation of personal, clinical, diagnostic, and drug-related factors tailored to the patient. During the study, participants will undergo a thorough assessment, complete health status and attitude questionnaires, and have any medication-related adverse events recorded at discharge. Follow-up contact occurs three months after discharge to check for hospital readmission or death. The primary outcome is the average number of drugs taken at baseline and about 30 days after discharge, with the study expected to continue until June 2026.
CONDITIONS
Brief Title
Applying a Multidisciplinary Intervention for Drug Adequacy in an Intermediate Care Hospital (AMIDA-ICH)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Older adults aged 65 years or older
- Have three or more chronic conditions requiring medical treatment
- Able to speak Spanish
- Able to provide informed consent or have a surrogate who can consent on their behalf
You will not qualify if you...
- Unable to provide informed consent
- Expected hospital stay less than 72 hours
- Estimated life expectancy less than 3 months
- Homeless
- Already participating in another drug trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - During hospital stay, at least 72 hours
Participants receive either usual care or a patient-centered multidisciplinary medication review conducted by a team including a geriatrician, clinical pharmacist, and nurse, focusing on medication adequacy.
1 multidisciplinary medication review visit during hospital stay
Duration - Approximately 30 days after discharge
Participants are assessed after discharge to evaluate medication use and outcomes approximately 30 days later.
1 follow-up visit (in-person or remote)
Trial Site Locations
Total: 1 location
1
Parc Sanitari Pere Virgili
Barcelona, Barcelona, Spain, 08023
Actively Recruiting
Research Team
A
Ana M de Andrés Lázaro, Pharmacist. PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here